Dr. Robert (Rob) Siegel is Vice President in the Laboratory for Experimental Medicine at Eli Lilly and Company. He received Ph.D. in Microbiology with minor in Biochemistry from Indiana University Bloomington. Rob completed postdoctoral training at the Los Alamos National Laboratory where he began his antibody engineering career that includes extensive work with both phage and yeast in vitro display systems. Rob joined Eli Lilly and Company in 2007 and most recently has collaboratively devised and implemented the large molecule portfolio preclinical immunogenicity risk assessment strategy. His laboratory focuses on antibody discovery / engineering and proteomics while working across all phases of drug development from target identification to registration. He is the author of > 50 peer-reviewed publications and holds 9 granted patents.